Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: Marked differences between various antipsychotic drugs

BMC Neuroscience

Volumn 7, Issue , 2006, Pages

  Fernø, Johan ^a,b   Skrede, Silje ^a,b   Vik Mo, Audun O ^a,b   Håvik, Bjarte ^a,b   Steen, Vidar M ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

7 DEHYDROCHOLESTEROL; ACETYL COENZYME A ACETYLTRANSFERASE; ACYL COENZYME A DESATURASE; CHLORPROMAZINE; CLOZAPINE; FATTY ACID SYNTHASE; GERANYLTRANSFERASE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; LOW DENSITY LIPOPROTEIN RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; STEROL REGULATORY ELEMENT BINDING PROTEIN; ZIPRASIDONE;

ARTICLE; ASTROCYTOMA CELL; BRAIN CELL; CELL LINE; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GLIA CELL; GLIOMA CELL; HUMAN; HUMAN CELL; LIPOGENESIS; NEUROBLASTOMA CELL; SCHIZOPHRENIA; TRANSCRIPTION INITIATION;

ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LIPOGENESIS; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 33750980390     PISSN: 14712202     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-7-69     Document Type: Article

References (42)

1. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA: Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 2001, 98:4746-4751.
2. Hof PR, Haroutunian V, Friedrich VLJ, Byne W, Buitron C, Perl DP, Davis KL: Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 2003, 53:1075-1085.
3. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V: White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003, 60:443-456.
4. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S: Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805.
5. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, Rachmanova V: Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001, 55:597-610.
6. Dietschy JM, Turley SD: Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004, 45:1375-1397.
7. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW: CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001, 294:1354-1357.
8. Remington G: Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J Psychiatry Neurosci 2003, 28:275-284.
9. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60:553-564.
10. Remington G, Kapur S: Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl) 2000, 148:3-15.
11. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
12. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lovlie R, Berge RK, Stansberg C, Steen VM: Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 2005, 5:298-304.
13. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109:1125-1131.
14. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, Goldstein JL: Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 2003, 100:12027-12032.
15. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL: Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 1997, 99:846-854.
16. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS: Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997, 99:838-845.
17. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL: Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 1996, 98:1575-1584.
18. Horton JD, Bashmakov Y, Shimomura I, Shimano H: Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci U S A 1998, 95:5987-5992.
19. Janowski BA, Shan B, Russell DW: The hypocholesterolemic agent LY295427 reverses suppression of sterol regulatory element-binding protein processing mediated by oxysterols. J Biol Chem 2001, 276:45408-45416.
20. Lange Y, Ye J, Rigney M, Steck TL: Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J Lipid Res 1999, 40:2264-2270.
21. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL: H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526.
22. Miyamoto S, Duncan GE, Marx CE, Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10:79-104.
23. Raeder MB, Ferno J, Glambek M, Stansberg C, Steen VM: Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett 2006, 395:185-190.
24. Lange Y, Steck TL: Cholesterol homeostasis. Modulation by amphiphiles. J Biol Chem 1994, 269:29371-29374.
25. Nohturfft A, DeBose-Boyd RA, Scheek S, Goldstein JL, Brown MS: Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc Natl Acad Sci U S A 1999, 96:11235-11240.
26. Adams CM, Reitz J, De Brabander JK, Feramisco JD, Li L, Brown MS, Goldstein JL: Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. J Biol Chem 2004, 279:52772-52780.
27. Adams CM, Goldstein JL, Brown MS: Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. Proc Natl Acad Sci U S A 2003, 100:10647-10652.
28. Saher G, Brugger B, Lappe-Siefke C, Mobius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA: High cholesterol level is essential for myelin membrane growth. Nat Neurosci 2005, 8:468-475.
29. Ness GC: Developmental regulation of the expression of genes encoding proteins involved in cholesterol homeostasis. Am J Med Genet 1994, 50:355-357.
30. Glantz LA, Lewis DA: Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000, 57:65-73.
31. Honer WG, Falkai P, Chen C, Arango V, Mann JJ, Dwork AJ: Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience 1999, 91:1247-1255.
32. Lewis DA: Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology 1997, 16:385-398.
33. Mirnics K, Middleton FA, Lewis DA, Levitt P: Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci 2001, 24:479-486.
34. Goritz C, Mauch DH, Pfrieger FW: Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Mol Cell Neurosci 2005, 29:190-201.
35. Pfrieger FW: Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 2003, 25:72-78.
36. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Muller-Oerlinghausen B, Rao ML, Riederer P, Zernig G: The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004, 37:243-265.
37. Kornhuber J, Schultz A, Wiltfang J, Meineke I, Gleiter CH, Zochling R, Boissl KW, Leblhuber F, Riederer P: Persistence of haloperidol in human brain tissue. Am J Psychiatry 1999, 156:885-890.
38. Weigmann H, Hartter S, Fischer V, Dahmen N, Hiemke C: Distribution of clozapine and desmethylclozapine between blood and brain in rats. Eur Neuropsychopharmacol 1999, 9:253-256.
39. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WTJ: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998, 155:751-760.
40. Freedman R: Schizophrenia. N Engl J Med 2003, 349:1738-1749.
41. Akslen LA, Andersen KJ, Bjerkvig R: Characteristics of human and rat glioma cells grown in a defined medium. Anticancer Res 1988, 8:797-803.
42. Winer J, Jung CK, Shackel I, Williams PM: Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 1999, 270:41-49.